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Nephropathy is a life-threatening complication of
diabetes mellitus and is the leading cause of end-
stage renal disease (ESRD) in developed countries
(1). Approximately 30% of insulin-dependent dia-
betes mellitus (IDDM) patients suffer from diabetic
nephropathy (1, 2), eventually undergoing renal dial-
ysis or transplantation. The features characteristic
of this disease include persistent albuminuria, a pro-
gressive decline in renal function, and, histopatho-
logically, mesangial expansion followed by glomeru-
losclerosis. To understand the pathogenesis of
diabetic nephropathy and to develop preventive and
therapeutic measures against it, suitable animal
models are needed. However, there has been no sin-
gle animal model that develops the renal changes
seen in humans (3). Spontaneously diabetic animals
such as nonobese diabetic (NOD) mice develop only
limited lesions, this being, at most, mild mesangial
sclerosis (4). The same is the case with chemically
induced diabetic rodents (5).
Exposure of proteins to reducing sugars like glucose
results in nonenzymatic glycation, which forms
reversible Schiff bases and Amadori compounds (6).
A series of further complex molecular rearrangements
then yields irreversible advanced glycation end prod-
ucts (AGEs) (6). In diabetes, prolonged hyperglycemia
superdrives this reaction and AGEs accumulate in the
circulating blood and in various tissues (6). AGE infu-
sion studies in experimental animals have suggested
a potential role of AGEs in the pathogenesis of dia-
betic nephropathy (7, 8) as well as retinopathy (9).
Receptor-dependent mechanisms are likely to work in
the AGE-induced tissue dysfunction. Receptor for
AGE (RAGE) is the best-characterized cell surface
molecule to which AGEs bind, and it has been shown
to be expressed in a variety of cell types (10–15).
Recent in vitro studies demonstrated that AGEs elic-
it vascular cell changes typical of diabetes. These
include angiogenic and thrombogenic responses of
endothelial cells (ECs) (12, 13), a decrease in pericytes,
(14) and the enhanced synthesis of ECM proteins by
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Vascular complications arising from multiple environmental and genetic factors are responsible for
many of the disabilities and short life expectancy associated with diabetes mellitus. Here we provide
the first direct in vivo evidence that interactions between advanced glycation end products (AGEs;
nonenzymatically glycosylated protein derivatives formed during prolonged hyperglycemic expo-
sure) and their receptor, RAGE, lead to diabetic vascular derangement. We created transgenic mice
that overexpress human RAGE in vascular cells and crossbred them with another transgenic line
that develops insulin-dependent diabetes shortly after birth. The resultant double transgenic mice
exhibited increased hemoglobin A1c and serum AGE levels, as did the diabetic controls. The double
transgenic mice demonstrated enlargement of the kidney, glomerular hypertrophy, increased albu-
minuria, mesangial expansion, advanced glomerulosclerosis, and increased serum creatinine com-
pared with diabetic littermates lacking the RAGE transgene. To our knowledge, the development of
this double transgenic mouse provides the first animal model that exhibits the renal changes seen
in humans. Furthermore, the phenotypes of advanced diabetic nephropathy were prevented by
administering an AGE inhibitor, (±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide
(OPB-9195), thus establishing the AGE-RAGE system as a promising target for overcoming this
aspect of diabetic pathogenesis.
J. Clin. Invest. 108:261–268 (2001). DOI:10.1172/JCI200111771.
renal mesangial cells (15). All of these changes are
RAGE-dependent, as evidenced by their cessation by
RAGE antisense or ribozyme (12–15).
In the present study, we constructed transgenic mice
that overexpress human RAGE in vascular cells
(RAGETg). When these mice were made diabetic by
crossbreeding with another transgenic mouse deficient
in the islet production of insulin (16), the resultant
double transgenic animals developed renal insuffi-
ciency and advanced glomerulosclerosis that resembled
human diabetic nephropathy. This in vivo approach
has thus established the functional importance of the
AGE-RAGE system in the development of diabetic
nephropathy, and the RAGE-overexpressing IDDM
mice are regarded as the first single animal model in
which the process of diabetes-induced kidney changes
leading to ESRD can be followed. The AGE-RAGE sys-
tem would seem to be a promising target for the pro-
phylaxis and therapy of diabetic complications, and a
study with (±)-2-isopropylidenehydrazono-4-oxo-thia-
zolidin-5-ylacetanilide (OPB-9195) (17) included in
this paper suggests that the inhibition of AGE forma-
tion could be an effective remedy.
Methods
Construction of transgenic mice and induction of diabetes. A
mouse flk-1 promoter previously reported to be active
in vascular ECs in vitro was used (18). The 0.9-kbp
fragments of the mouse flk-1 promoter and the 3.4-
kbp fragments of the entire exonic and intronic region
of the human RAGE gene (provided by T. Ikemura and
K. Sugaya, National Institute of Genetics, Mishima,
Japan) were ligated in the correct orientation by a
modified polymerase chain reaction method (19).
Primers used in the PCR reactions were 5′-GAG-
GTACCAGTTCACAACCGAAATGTCTTCTAGGG-3′ and 5′-
CTGCTGTTCCGGCTGCCATCCTGCACCTCGCGC-
TGGGCA-3′ (nucleotides –623 to –597, +280 to +299)
for mouse flk-1 (18), and 5′-ATGGCAGCCGGAACAGC-
AGTT-3′ and 5′-GAGCGGCCGCATCTTCTCCCCAACTTG-
AGTAGA-3′ (nucleotides 6665–6685, 10027–10049) for
human RAGE gene (20), containing KpnI and NotI
sites (underlined sequences), respectively. The result-
ant 4.3-kbp hybrid gene was microinjected into fertil-
ized eggs as described (16). Six out of 24 newborn off-
spring carried the transgene, as detected by PCR
analyses of DNA from tail tissue using primers for 
flk-1 promoter (5′-AGGGACGGAGAAGGAGT-3′: +240 to
+256) (18) and human RAGE gene (5′-TCACCCCACA-
GACTGAG-3′: 6704–6720) (20).
RAGETg was crossbred with another transgenic mouse
carrying human cDNA for inducible nitric oxide synthase
(iNOS) under the control of the insulin promoter (iNOS-
Tg) (16). There was no expression of iNOS protein in the
kidney (16). The resultant four groups of male littermates
were used for analysis after PCR verification of the trans-
genes. Each group was fed either normal or 0.28% OPB-
9195 mixed mouse chow (provided by Fujii Memorial
Research Institute, Otsuka Pharmaceutical, Ohtsu,
Japan) from 1 to 6 months after birth. The levels of blood
glucose and hemoglobin A1c (HbA1c) were measured from
tail vein blood using Dexter Z sensor and DCA2000 ana-
lyzer (Bayer Medical, Tokyo, Japan) (21), respectively.
The procedures were approved by the Institutional
Animal Care and Use Committee guidelines at
Tohoku University and at Kanazawa University Grad-
uate School of Medical Science.
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Figure 1
Generation and characterization of RAGE transgenic mice. (a)
Transgene construct. The human RAGE genomic sequence, begin-
ning with the initiator codon in exon 1 and ending 129 bp down-
stream from the last exon, was placed under the transcriptional con-
trol of the murine flk-1 promoter. The flk-1 fragment encompassed
the 5′ untranslated region (dark gray box), sharing the ATG codon
with the RAGE fragment. (b) Transgene-derived transcripts. Total
RNAs isolated from various tissues of line 102 and 103 heterozy-
gotes were analyzed by RT-PCR. The granulation tissue — the focus
of angiogenesis — was prepared by punching out an area of the dor-
sal skin about 4–5 mm in diameter. The PCR-amplified products
had a chain length of 354 bp as predicted and were sequence-veri-
fied. (c) Immunofluorescence staining of kidneys from line 102
RAGETg or nontransgenic control at 4 months of age using anti-
human RAGE-specific polyclonal Ab. Original magnification, ×430.
(d) Translation products of the transgene. Extracts of isolated ECs
from renal cortex or peripheral blood monocytes of line 102
RAGETg or the nontransgenic control were immunodetected with
the human RAGE Ab. Specific bands were marked at 55 kDa in line
102 RAGETg EC and monocyte extracts. VE-cad, VE-cadherin, i.e.,
an EC marker; CD14, a monocyte marker.
RT-PCR. Total RNA was isolated from various tissues,
and from isolated renal glomeruli, of transgenic or con-
trol mice using the guanidinium thiocyanate method,
and reverse-transcribed (22). The isolation of glomeruli
from mouse kidneys was performed as described (23).
Primer sequences for human RAGE mRNA detection
were 5′-AAGCCCCTGGTGCCTAATGAG-3′ and 5′-CAC-
CAATTGGACCTCCTCCA-3′ (nucleotides 508–528 and
728–747 in GenBank AB036432); those for mouse
RAGE mRNA detection were 5′-CCTGGGTGCTG-
GTTCTTGCTCT-3′ and 5′-GATCTGGGTGCTCTTACG-
GTCC-3′ (nucleotides 31–52 and 1209–1230 in Gen-
Bank L33412); those for mouse GAPDH mRNA
detection were the same as described (24). The amounts
of total RNA templates (100 ng) and the numbers for
amplification cycles (35 cycles for human RAGE and 30
cycles for mouse RAGE and GAPDH) were chosen in
quantitative ranges. An aliquot of each RT-PCR prod-
uct was electrophoresed on 2% agarose gel containing
ethidium bromide.
Isolation of ECs and monocytes, and Western blot analysis.
ECs from mouse renal cortex were cultivated for 2
days in a gelatin-coated plate after isolation by specif-
ic selection with rat anti-mouse CD31/PECAM-1
mAb–coated (MEC7.46; HyCult Biotechnology b.v.)
magnetic beads (Dynabeads M-450 sheep anti-rat IgG;
Dynal, Oslo, Norway) as described (25). Monocytes
were isolated from peripheral blood by Ficoll-Paque
(Pharmacia Biotech AB, Uppsala, Sweden) centrifuga-
tion followed by magnetic cell sorter (MACS; Miltenyi
Biotec, Bergisch Gladbach, Germany) using
CD11b/Mac-1α Ab–coated MicroBeads (Miltenyi
Biotec) according to the manufacturer’s instructions
(26). Cells were homogenized in PBS, 1% NP-40, 0.5%
deoxycholate, 10 mM EDTA, 0.1% SDS, and 1.0 mM
PMSF, and centrifuged at 15,000 g for 30 minutes at
4°C. Supernatants were used for protein assay. Pro-
tein concentrations were determined using Coomassie
Protein Assay Reagents (Pierce Chemical Co., Rock-
ford, Illinois, USA) by the method of Bradford (27).
Proteins were electrophoresed on 10% SDS-PAGE and
transferred electrophoretically to polyvinilidene diflu-
oride membranes. Membranes were blocked with 5%
nonfat dry milk in PBS and 0.1% Tween-20, and then
incubated with 1:100 dilution of goat anti–vascular
endothelial-cadherin (anti–VE-cadherin) polyclonal
Ab (Santa Cruz Biotechnology Inc., Santa Cruz, Cali-
fornia, USA), 1:100 dilution of goat anti-mouse CD14
polyclonal Ab (Santa Cruz Biotechnology Inc.), or
0.25 µg/ml of immunoaffinity-purified anti-RAGE
polyclonal Ab raised against 16-amino-acid synthetic
peptides (QRRQRRGEERKAPENQ) that correspond-
ed to amino acid residues 364–379 of the human
RAGE protein (11). After incubation with 1:2,000
dilution of anti-goat or anti-rabbit IgG conjugated to
horseradish peroxidase, the immune complexes were
visualized with an enhanced chemiluminescence
detection system (ECL; Amersham Pharmacia
Biotech, Piscataway, New Jersey, USA).
Determination of AGE concentration. Serum Nε-car-
boxymethyl-lysine (CML) and non-CML AGEs were dif-
ferentially determined using a competitive ELISA as
described (28). One U/ml of CML or non-CML AGEs
corresponded to a protein concentration of 1 µg/ml
CML-BSA or non-CML AGE-BSA, respectively.
Determination of urine albumin/creatinine ratio and serum
creatinine. Urinary or serum creatinine was measured by
the Jaffe reaction (29). The level of urinary albumin was
measured by ELISA with sheep anti-mouse albumin as
described (4, 30). The ratio of urinary albumin to crea-
tinine was then calculated.
Renal histology and morphometric analyses. Kidneys were
processed for light microscopy examination, and the
severity of the renal sclerosis was scored by multiple ana-
lysts on an arbitrary scale from 0 to 4 (4, 31, 32). The
mean glomerular volume was determined as described
previously (4, 30). To quantify mesangial expansion,
periodic acid-Schiff–positive (PAS-positive) area in the
mesangium was determined as mesangium area using
an image analyzer with a microscope (Image Processor
for Analytical Pathology; Sumitomo Chemical Co.,
Tokyo, Japan) (33). Immunofluorescence analysis was
carried out as described (30, 34) using an affinity-puri-
fied polyclonal Ab specific to human RAGE raised
against 10-amino-acid synthetic peptides (PLVP-
NEKGVS) corresponding to amino acid residues
163–172 of the human RAGE protein (11), anti-CML
Ab, and anti–non-CML AGE Ab (28).
Results
Expression of RAGE transgene. We created RAGETg by
introducing into fertilized ova of C57BL/6J × CBA/J F1
mice a transgene carrying human RAGE genomic DNA
under the control of the murine flk-1 promoter, which
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Figure 2
Renal changes in the early stage. (a) Kidney weight/body weight ratio.
Inset: Sagittal section of the kidney at 4 months of age. Bar, 5 mm.
(b) Albuminuria. Filled circles, DM+RAGETg+; open circles,
DM+RAGETg–; filled squares, DM–RAGETg+; open squares,
DM–RAGETg–. Data are mean ± SEM. *P < 0.02, †P < 0.05 compared
with DM+RAGETg–. Statistical analysis was performed by t test.
acts in ECs (18) (Figure 1a). PCR analysis revealed that
five out of six potentially transgenic mice exhibited
transgene transmission into their germlines. Two inde-
pendent lines, 102 and 103, carrying high copy num-
bers, were used for subsequent experiments. RT-PCR
analysis with human RAGE-specific primers revealed
active transcription of the transgene in the lung, skin
granulation tissue (the focus of angiogenesis), kidney,
heart, aorta, and eyes of each line, but not in controls
(Figure 1b). Immunofluorescent examination of kid-
ney sections demonstrated that glomeruli of RAGETg
were positively stained for human RAGE in an EC pat-
tern, but not in the control (Figure 1c). Immunoblot-
ting of cell extracts from renal cortical ECs demon-
strated the overexpression of RAGE proteins in
RAGETg (Figure 1d). Expression of the RAGE protein
was also detected in monocytes from peripheral blood
of RAGETg (Figure 1d).
Induction of diabetes. There are several means to induce
diabetes in experimental animals (35, 36). Chemical or
surgical maneuvers for diabetes induction might, how-
ever, cause some diversity among individual animals in
terms of the extent of severity and the onset of diabetes.
Accordingly, we employed a genetic approach by which
a diabetic state and advanced glycation as well would
be most stably induced. That is, RAGETg was crossbred
with iNOSTg that consistently develops IDDM as early
as 1 week after birth due to the iNOS-mediated selec-
tive destruction of insulin-producing pancreatic β cells
(16). RAGETg was back-crossed to the nontransgenic
parental strain CD-1 of iNOSTg for 4 or 5 generations
to unify the genetic background. Then, the heterozy-
gotes of male iNOSTg and female RAGETg were
mated, thereby yielding four groups of littermates at
five or six generations with CD-1 background, which
carried both, either, or neither of the transgenes. They
were tentatively designated DM+RAGETg+,
DM+RAGETg–, DM–RAGETg+, and DM–RAGETg–,
since the mice carrying the iNOS transgene exclusively
developed hyperglycemia regardless of the presence or
absence of the RAGE transgene. Blood analysis revealed
sustained hyperglycemia and high HbA1c levels in the
former two groups but not in the latter two (Table 1).
There were no significant differences in these indices
between DM+RAGETg+ and DM+RAGETg– (Table 1).
Body weight was also invariant between the two groups
at all time points tested during the 6-month observa-
tion period (data not shown). To determine the levels
of circulating AGEs, serum was differentially measured
by competitive ELISA for CML (derivative of AGEs
mainly formed by peroxidation) and for non-CML
AGEs (28). Serum non-CML AGE levels rapidly
increased with time in both DM+RAGETg+ and
DM+RAGETg– mice, but without significant differ-
ences between them at each time point (Table 1). There
was a tendency of higher serum CML levels in the dia-
betic groups than in the nondiabetic groups, but with-
out significant differences (Table 1). These findings
were comparable to observations in human diabetic
and nondiabetic subjects (28). With the 103 line, simi-
lar results were obtained by blood glucose, HbA1c, and
serum AGE assays (data not shown).
Phenotypic changes of the kidney. The kidney weight/body
weight ratios from DM+RAGETg+ showed a marked
increase when compared with age-matched
DM+RAGETg– mice (Figure 2a). The urinary
albumin/creatinine ratio became significantly higher in
DM+RAGETg+ than in the other groups at 4 months
(Figure 2b). The microscopic lesions noted in the dia-
betic groups consisted of glomerular cell proliferation,
glomerular hypertrophy, mesangial expansion, and
glomerulosclerosis. DM+RAGETg+ showed accelerated
increases in glomerular cell proliferation and glomeru-
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Figure 3
Glomerular changes in the early stage. Glomerular cell proliferation
(left) and glomerular volume (right) at 2 months of age. Data are
mean ± SEM. *P < 0.05. Statistical analysis was performed by t test.
Figure 4
Renal changes in the late stage. PAS staining of thin kidney sections
from line 102 DM+RAGETg+ (a), DM+RAGETg– (b), DM–RAGETg+
(c), and DM–RAGETg– (d) at 4 months of age and DM+RAGETg+ (e)
at 8 months of age. Original magnification, ×670.
lar volume in comparison with DM+RAGETg– mice (Fig-
ure 3). Diffuse glomerulosclerosis progressed as the mice
aged in both groups. However, there was a conspicuous
difference in the severity of mesangial expansion and
glomerulosclerosis at 4 months between DM+RAGETg+
and DM+RAGETg–, as evidenced by increased accumu-
lation of PAS-positive materials in the mesangial area of
the former (Figure 4, a–d). Quantitative examinations of
at least 50 glomeruli per mouse revealed significant
increases in mesangium area, mesangium fraction (rela-
tive mesangium area calculated as mesangium
area/glomerular area ratio) (Figure 5), and sclerosis index
in DM+RAGETg+ compared with DM+RAGETg– mice at
4 months of age (Figure 6a). Immunostaining showed
that significant amounts of not only non-CML AGEs
but also CML accumulated in the mesangial area in the
diabetic mice, but not in nondiabetic mice (Figure 7,
a–d). At 6 months of age, the serum creatinine level of
DM+RAGETg+ increased to 1.24 ± 0.07 mg/dl, being the
highest among the groups (Figure 6a). Further, typical
nodular lesions and hyaline arteriosclerosis were noted
at 8 months of age in DM+RAGETg+ (Figure 4e). Since
hypertension has been known to be another risk factor
for progressive glomerular disease (37), the blood pres-
sure was monitored. Though DM+RAGETg+ showed a
slightly higher value at 6 months of age, there was no sta-
tistically significant difference in systolic blood pressure
among the four groups (DM+RAGETg+, 135 ± 8 mmHg;
DM+RAGETg–, 108 ± 10 mmHg; DM–RAGETg+, 109 ± 9
mmHg; DM–RAGETg–, 108 ± 10 mmHg). Experiments
with the line 103 series revealed a similar tendency in all
of the above indices.
Upregulation of endogenous mouse RAGE mRNA in dia-
betes. Since AGE ligands themselves have been shown to
induce the transcription of the RAGE gene (38), we
determined the endogenous mouse RAGE mRNA lev-
els along with the transgene-derived human RAGE
mRNA levels in renal glomeruli by RT-PCR with
mouse- or human-specific primer pairs. The endoge-
nous RAGE mRNA levels were increased in glomeruli
of DM+RAGETg+ since 2 months of age and in
DM+RAGETg– too at 4 months of age (Figure 7e). On
the other hand, the transgene expression under the
control of flk-1 promoter was invariant under diabetic
conditions (Figure 7e).
Suppression of diabetic nephropathy by OPB-9195. We then
conducted an intervention study with OPB-9195, a thi-
azolidine derivative that can inhibit AGE formation by
blocking carbonyl groups on glycation intermediates
(17). When the mice had received OPB-9195 orally for 5
months, the serum non-CML and CML AGE levels of
both DM+RAGETg+ and DM+RAGETg– were signifi-
cantly reduced to levels similar to those of nondiabetic
mice, with blood glucose and HbA1c being essentially
unaffected (Table 1). The OPB-9195 treatment signifi-
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Table 1 
Diabetes-related blood indices in line 102
Group Age Mice Blood glucose HbA1c CML Non-CML AGEs
(mo) (n) (mg/dl) (%) (U/ml) (U/ml)
DM+RAGETg+ 2 4 509 ± 61 8.0 ± 0.6 4.1 ± 0.4 10.3 ± 0.4
4 3 609 ± 94 9.5 ± 0.1 3.7 ± 0.6 11.9 ± 1.0
6 7 547 ± 13 8.3 ± 0.6 7.7 ± 0.1 24.2 ± 1.3
OPB 6 8 693 ± 26 9.4 ± 0.5 5.4 ± 0.4A 14.2 ± 0.8C
DM+RAGETg– 2 6 482 ± 22 8.2 ± 0.4 3.4 ± 0.5 7.3 ± 2.3
4 5 447 ± 45 9.1 ± 0.5 5.1 ± 0.8 14.4 ± 2.5
6 9 503 ± 19 7.5 ± 0.8 7.3 ± 0.6 20.7 ± 2.5
OPB 6 5 586 ± 74 8.9 ± 0.9 4.3 ± 1.0B 10.2 ± 2.6D
DM–RAGETg+ 2 6 177 ± 5 3.2 ± 0.2 2.9 ± 0.6 2.5 ± 1.0
4 6 157 ± 3 3.8 ± 0.3 3.3 ± 0.6 6.4 ± 1.6
6 11 134 ± 4 <2.5 7.6 ± 0.3 20.2 ± 1.7
OPB 6 4 145 ± 16 <2.5 6.3 ± 1.0 13.2 ± 3.7
DM–RAGETg– 2 3 188 ± 8 3.3 ± 0.1 2.6 ± 1.0 2.8 ± 0.6
4 5 157 ± 4 3.4 ± 0.1 3.0 ± 0.1 4.4 ± 0.5
6 11 125 ± 5 <2.5 6.2 ± 0.4 12.6 ± 1.0
OPB 6 10 169 ± 9 <2.5 5.0 ± 0.7 8.7 ± 1.1
Data are expressed as the mean ± SEM. OPB, oral OPB-9195 administration for 5 months. AP < 0.002 and BP < 0.05 compared with CML values of DM+RAGETg+
and DM+RAGETg– at 6 months of age without OPB-9195 treatment, respectively. CP < 0.002 and DP < 0.05 compared with non-CML AGE values of DM+RAGETg+
and DM+RAGETg– at 6 months of age without OPB-9195 treatment, respectively. Statistical analysis was performed by t test. A high non-CML AGE level was
noted in DM–RAGETg+ at 6 months; the reason for this may be partly explained by hemolysis.
Figure 5
Mesangial expansion. Mesangium area (left) and mesangium frac-
tion (right). Numbers on columns indicate months of age. Data are
mean ± SEM. *P < 0.05. Statistical analysis was performed by t test.
cantly suppressed the increases in the kidney
weight/body weight ratio (Figure 6b) and the sclerosis
index and serum creatinine (Figure 6a) of DM+RAGETg+
at 6 months of age. A similar tendency was observed in
experiments with the line 103 series (data not shown).
Discussion
In its early phase, diabetic nephropathy is characterized
by increased albuminuria, glomerular hypertrophy, and
nephromegaly (37). Mesangial expansion, glomeru-
losclerosis, and increased serum creatinine then follow
in the late phase (37). In this study, the diabetic mouse
itself, which we used to mate with the RAGETg, showed
glomerular hypertrophy until 4 months of age and pro-
gressive mesangial expansion and glomerulosclerosis
afterward. Furthermore, overexpression of human
RAGE gene in ECs, which normally were only faintly
stained for RAGE protein in renal arteries, arterioles, and
glomerular capillaries (39–41), was found to result in a
significant acceleration of all of the early- and late-phase
indices of diabetic nephropathy. Because the extent of
this acceleration was roughly proportional to the degree
of RAGE transgene expression, and because circulating
levels of AGEs and their deposition in renal glomeruli
were essentially invariant between the IDDM animals
carrying or not carrying the RAGE transgene, it was con-
sidered to be the level of RAGE expression that had rate-
limited the progression of diabetic nephropathy. The
higher expression of RAGE induced the earlier and high-
er expression of endogenous mouse RAGE in renal
glomeruli under diabetic conditions (Figure 7e). The
upregulation of the endogenous RAGE would then
superdrive the development of the renal lesions in
DM+RAGETg+. In addition, oral administration of a thi-
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Figure 6
(a) Sclerosis index and serum creatinine level. (b) Kidney weight/body weight ratio. Open bars, animals not treated with OPB-9195; filled
columns, animals treated with OPB-9195. Numbers on columns indicate months of age. Data are mean ± SEM. *P < 0.05, †P < 0.005, 
#P < 0.001. Statistical analysis was performed by t test.
Figure 7
Stain for non-CML AGEs (a and b) and CML (c and d) in the kidneys from 4-month-old line 102 DM+RAGETg+ (a and c) and DM–RAGETg–
(b and d) mice. Glomeruli were stained for non-CML AGEs and CML in DM+RAGETg– to extents similar to those in DM+RAGETg+ but were
much less stained in DM–RAGETg+ and DM–RAGETg– mice. Original magnification, ×330. (e) Upregulation of mouse RAGE mRNA in dia-
betic glomeruli. Total RNAs isolated from glomeruli of each of the four groups in line 102 were analyzed by RT-PCR. mRAGE, mouse RAGE
mRNA; hRAGE, human RAGE mRNA. Numbers indicate months of age.
azolidine compound, OPB-9195, significantly sup-
pressed the development of the renal insufficiency,
nephromegaly, and glomerulosclerosis in DM+RAGETg+
without affecting the levels of blood glucose or HbA1c.
OPB-9195 is known to inactivate carbonyl intermediates
of nonenzymatic glycation with an activity about one
order of magnitude more potent than that of
aminoguanidine (17). The prevention of diabetic
nephropathy by OPB-9195 in the transgenic mice was
associated with a decrease in AGEs, though this could
reflect other hitherto unknown properties of the drug.
These results indicate that endothelial RAGE and its
engagement by AGEs contribute to the full expression of
diabetic nephropathy, and that the AGE-RAGE system
could become a target for intervention in this disease.
Then, how does the AGE-RAGE interaction lead to
such kidney changes? It is reported that AGE-RAGE
interactions upregulate the production of various
cytokines and growth factors such as TNF-α (42),
PDGF (22), and VEGF (12) via oxidant stress forma-
tion. TNF-α and VEGF are known to increase vascular
permeability and to diminish barrier properties (43).
This may underlie the increased albuminuria. AGE-
RAGE interactions also have been shown to stimulate
endocytosis and transcytosis of AGEs in ECs (44), thus
probably causing the abluminal accumulation of
AGEs, to which mural cells like mesangial cells would
then be exposed. AGE-induced oxidant stress might
also accelerate CML production in situ in the glomeruli
(45). The exposure to AGEs has been shown to be fol-
lowed by the transcriptional induction of the mesan-
gial cell synthesis of type IV collagen, a major compo-
nent of the expanded ECM in diabetic nephropathy
(46, 47). This induction was also proved to be mediat-
ed by RAGE (15). In addition, positive staining for type
I and IV collagen was noted in the glomeruli of the
present nephropathy model (data not shown). More-
over, EC expression of VCAM-1 is also known to be
induced by AGE engagement of RAGE (48), enhancing
mononuclear cell adhesion to the capillary wall, which
would allow macrophage invasion into the mesangial
area. This may provide an additional source of
cytokines such as TGF-β that can contribute to the
development of glomerulosclerosis. The flk-1 promot-
er employed to construct RAGETg in this work is
known to also work in the monocyte-macrophage lin-
eage (49). The RAGE overexpression in monocytes (Fig-
ure 1d) is considered to be consistent with this notion
and may augment the interaction with AGE on invad-
ed macrophages, thereby contributing to accelerating
the progression of nephropathy in the present model.
RAGE engagement by endogenous ligands, namely
amphoterin (50) and EN-RAGE (S100/calgranulins;
ref. 51), is reportedly involved in the network formation
of cerebral neurons and in proinflammatory reactions,
respectively. The S100/calgranulins are known to be
released from activated inflammatory cells, including
mononuclear phagocytes as well as polymorphonu-
clear leukocytes and lymphocytes (52). The immuno-
fluorescence analysis of the kidney sections revealed
that renal glomeruli were stained for S100/calgranulins
in diabetic (DM+RAGETg+ and DM+RAGETg–) but not
in nondiabetic (DM–RAGETg+ and DM–RAGETg–)
groups, the heaviest stain being marked in
DM+RAGETg+ (data not shown). This suggests that the
diabetic kidney contains two RAGE ligands, both
nonenzymatically glycated adducts and S100/calgran-
ulin proteins, and that S100/calgranulins accumulat-
ing in the kidney lesions could further activate ECs and
monocytes/macrophages via their engagement of
RAGE. AGEs are senescent proteins that accumulate
during prolonged diabetic exposure, and can also
engage cell surface RAGE, this resulting in the deterio-
ration of vascular functions (12, 15, 53). Diabetic com-
plications appear to exploit molecular devices primari-
ly evolved for development and survival.
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